Dupilumab (Dupixent®) – first-in-class, PBS-listed IL-4 receptor alpha biologic (targeting IL-4 and IL-13) for uncontrolled severe asthma

Sponsored by Sanofi Genzyme

An estimated 2.7 million Australians have asthma and in 3–10% of cases, this is considered to be severe.1,2 From 1 April 2021, the first-in-class biologic targeting IL-4 and IL-13, dupilumab, became available on the PBS for the treatment of uncontrolled severe asthma in eligible patients.3 To better understand what this means for the management of ...

Already a member?

Login to keep reading.

© 2021 the limbic